ClinicalTrials.gg
CompletedNCT06206421Starlight 3Updated Apr 8, 2026

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

A Phase 3 interventional study of Fezolinetant and Placebo in Hot Flashes, sponsored by Astellas Pharma Inc. Completed at 24 sites in Japan. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
8th of 16
277 · median 249
Started
2024
with 2 others
Phase 3
10 of 16
2 open now
Registered
9th of 16
by date
Lead sponsor
4 of 16
Astellas Pharma Inc

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 8th largest by enrollment, is one of 3 that started in 2024, is one of 10 in phase 3, and was the 9th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed.

Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia.

In this study fezolinetant will be used to treat hot flashes in Japanese women going through menopause. This study will confirm the safety of fezolinetant and how well the women tolerate the treatment.

Women will either take fezolinetant or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it.

The women will take 1 tablet of the study medicine (fezolinetant or the placebo) once a day for up to 52 weeks.

During the study, the women will visit their study clinic for a check-up about every 4 weeks for up to 52 weeks (1 year). At each visit they will be asked if they had any medical problems. Other checks will include a medical examination and vital signs (temperature, blood pressure and pulse). At some visits, the women will have an ECG to check their heart rhythm and some blood and urine samples will be taken for laboratory tests. During a couple of visits, women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs.

The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or the placebo).

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • menopause;
  • ESN364;
  • vasomotor symptoms;
  • fezolinetant;
  • VEOZAH™
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant confirmed as menopausal per one of the following criteria at the screening visit (visit 1):

    • For a participant: Spontaneous amenorrhea for >/=12 consecutive months; Spontaneous amenorrhea for >/=6 months with biochemical criteria of menopause (follicle-stimulating hormone (FSH) > 40 IU/L); Having had bilateral oophorectomy >/=6 weeks prior to the screening visit (visit 1) (with or without hysterectomy); Having had hysterectomy without bilateral oophorectomy with the biochemical criteria of menopause (FSH > 40 IU/L); or Having been confirmed to be post-menopausal in the 2693-CL-0310 study.
    • For a peri-menopausal participant: Spontaneous amenorrhea for >/=60 days but \< 6 consecutive months 2 times in the 2 most recent menstrual cycles with biochemical criteria of peri-menopause (FSH > 25 IU/L); or Spontaneous amenorrhea for >/=6 months but \< 12 consecutive months with biochemical criteria of peri-menopause (FSH > 25 IU/L and ≤ 40 IU/L); Having had hysterectomy without bilateral oophorectomy with the biochemical criteria of peri-menopause (FSH > 25 IU/L and ≤ 40 IU/L).
  • Participant is seeking treatment for relief of vasomotor symptoms (VMS) associated with menopause.
  • Female participant:

    • Is not pregnant and at least 1 of the following conditions apply: Not a women of (WOCBP); WOCBP who has a negative urine pregnancy test day 1 (visit 2) and agrees to follow the guidance from the time of through at least 21 days after final study intervention administration.
    • Must not be breastfeeding or lactating starting at screening and throughout the period and for 21 days after final study intervention administration.
    • Must not donate ova starting at first administration of study intervention and throughout the investigational period and for 21 days after final study intervention administration
  • Participant agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of an undiagnosed uterine bleeding within the 6 months prior to the screening visit (visit 1).
  • Participant has a current malignant tumor or history (except for a participant who has not received treatment for malignant tumors for at least 5 years before acquisition and was not considered to have recurrence) of a malignant tumor except for non- basal cell carcinoma of the skin.
  • Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) that could confound interpretation of the study outcome.
  • Participant uses a prohibited therapy (hormone therapy, hormone replacement therapy (HRT), hormonal , any treatment for VMS [prescription medications, over-the-counter, or herbal/Kampo medicines] or strong or moderate cytochrome P450 1A2 (CYP1A2) inhibitors and is not willing to wash out or discontinue use of such drugs from screening visit (visit 1) through the follow-up visit (visit 16) or it is not medically appropriate to discontinue such drugs for the duration of the study.
  • Participant has been randomized/registered in a clinical trial with fezolinetant previously or had previous exposure to marketed fezolinetant elsewhere.
  • Participant has a present or previous history of participation in this study.
  • Participant has received any therapy within 28 days or 5 half-lives, whichever is longer, prior to screening visit (visit 1).
  • Participant has an unacceptable result from the transvaginal ultrasound (TVU) assessment at screening (i.e., full length of endometrial cavity cannot be visualized or presence of abnormal findings).
  • Participant has documentation of a clinically significant abnormal Papanicolaou (Pap) test (or equivalent cervical cytology) within 12 months prior to the screening visit (visit 1) or at screening.
  • Participant has active liver disease, jaundice, or elevated liver aminotransferases ( (ALT) or aspartate aminotransferase (AST)), elevated total (TBL) or direct bilirubin (DBL), elevated (INR), or elevated alkaline phosphatase (ALP) at screening. A participant with mildly elevated ALT or AST up to \< 1.5 × (ULN) can be enrolled if TBL and DBL are normal. Participant with mildly elevated ALP (up to \< 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Participant with Gilbert's syndrome with elevated TBL may be enrolled as long as DBL, and reticulocytes are normal.
  • Participant has creatinine > 1.5 × ULN or estimated using the Modification of Diet in Renal Disease formula \</=30 mL/min/1.73 m\^2 at screening.
  • Participant has positive hepatitis serology panel (i.e., positive surface (HBs) antigen and/or positive virus (HCV) antibody) at screening. If HCV antibody test result is equivocal, hepatitis C virus ribonucleic acid (HCV RNA) test at study site is allowed. Participant can be enrolled if that result is normal or not abnormal.
  • Participant is not in good general health as determined on the basis of medical history and general physical examination performed at the screening; hematology parameters, biochemistry parameters, pulse rate, blood pressure, (ECG) outside the reference range for the population studied, or is showing clinically relevant deviations.
  • Participant has a history of suicide attempt or suicidal behavior within 12 months prior to study enrollment or suicidal ideation within 12 months prior to study enrollment (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS)), or is at significant risk to commit suicide at day 1 (visit 2).
  • Participant is unable or unwilling to complete the study procedures.
  • Participant has any condition which makes the participant unsuitable for study participation.
  • Participant has a known or suspected to fezolinetant or any components of the formulation used.
  • Participant is the investigator or a member of the study site staff.
  • Participant is an employee of Astellas, the study-related contract research organizations (CROs) or site management organizations.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    Fezolinetant

    Participants will receive fezolinetant once daily for 52 weeks.

    Drug: Fezolinetant

  • Experimental
    Placebo

    Participants will receive matching placebo once daily for 52 weeks.

    Drug: Placebo

Interventions

  • oral

    Also known as: ESN364;, VEOZAH™

  • DrugPlacebo

    oral

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

    Time frame: Up to Week 55

Secondary outcomes

  1. Change from baseline in endometrial thickness in post-menopausal participants

    Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).

    Time frame: Baseline and up to Week 52

  2. Number of participants with laboratory value abnormalities and/or AEs

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to Week 55

  3. Number of participants with vital sign abnormalities and/or AEs

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to Week 55

  4. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to Week 52

  5. Pharmacokinetics (PK) of fezolinetant in plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Up to Week 52

  6. Pharmacokinetics (PK) of metabolite ES259564 in plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Up to Week 52

07

Study locations

24 sites
  • Daido Clinic
    Nagoya, Aichi-ken, Japan
  • Juno Vesta Clinic hatta
    Matsudo-shi, Chiba, Japan
  • Mori Ladies Clinic
    Fukuoka, Fukuoka, Japan
  • Kotoni Ladies Clinic
    Sapporo, Hokkaido, Japan
  • M's Ladies Clinic
    Sapporo, Hokkaido, Japan
  • NISHIKAWA Women's Health Clinic
    Sapporo, Hokkaido, Japan
  • Motomachi Ladies Clinic
    Yokohama, Kanagawa, Japan
  • Women's Clinic LUNA Yokohama Motomachi
    Yokohama, Kanagawa, Japan
  • Chieko Yukika Lady's Clinic
    Sendai, Miyagi, Japan
  • GyNet Medical Corporation Minamimorimachi Ladies' Clinic
    Osaka, Osaka, Japan
  • Ninomiya Ladies Clinic
    Osaka, Osaka, Japan
  • Rikako Ladies Clinic
    Osaka, Osaka, Japan
  • Tennoji Chihiro Women's Clinic
    Osaka, Osaka, Japan
  • Shimizu Ladies Clinic
    Sakai-shi, Osaka, Japan
  • jMOG Medical Corporation Tanabe Ladies' Clinic
    Takatsuki-shi, Osaka, Japan
  • Marunouchi no Mori Ladies Clinic
    Chiyoda-ku, Tokyo, Japan
  • Ginza Yoshida Medical Clinic
    Chuo-ku, Tokyo, Japan
  • Medical Corporation Asbo Tokyo Asbo Clinic
    Chuo-ku, Tokyo, Japan
  • Medical Corp.SEIKOUKAI New Medical Research System Clinic
    Hachioji-shi, Tokyo, Japan
  • Kichijyoji Ladies Clinic
    Musashino-shi, Tokyo, Japan
  • Shimamura Memorial Hospital
    Nerima-ku, Tokyo, Japan
  • Yukawa Women'S Clinic
    Nishi-Tokyo-shi, Tokyo, Japan
  • Shimodaira Ladies Clinic
    Suginami-ku, Tokyo, Japan
  • Medical Corporation Associa Tamacenter Ladies Clinic
    Tama-Shi, Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Mar 2026, 24 months.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 16, 2024
StartActual
Feb 22, 2024
Primary completionActual
Mar 19, 2026
CompletionActual
Mar 19, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06206421
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Feb 22, 2024
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026
Last update
Apr 8, 2026

Study contacts

Associate Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion